Background: Because of the prevalence of smoking in the veteran population, non-small-cell lung cancer (NSCLC) remains a significant cause of morbidity and mortality. The objectives of our study were to evaluate the extent of durable clinical benefit (DCB) to pembrolizumab in veterans with metastatic NSCLC and to identify clinical determinants of DCB.
Materials And Methods: Prospective clinical data on veterans receiving pembrolizumab were collected.